Detection and treatment of CD30+ cancers
US-10444241-B2 · Oct 15, 2019 · US
Detection and treatment of CD30+ cancers
US11366118B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11366118-B2 |
| Application number | US-201916571035-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 13, 2019 |
| Priority date | Feb 10, 2012 |
| Publication date | Jun 21, 2022 |
| Grant date | Jun 21, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a CD30 positive cancer, comprising administering an effective regimen of a CD30-directed therapy to a patient having a cancer selected from ovarian serous carcinoma, triple negative breast cancer, anaplastic thyroid carcinoma, pancreatic carcinoma or adenocarcinoma, small cell lung cancer, anal squamous cell carcinoma, Leydig cell tumor and Sertoli cell tumor, having detectable expression of CD30, wherein the CD30-directed therapy is an antibody drug conjugate, which is brentuximab vedotin. 2. The method of claim 1 , wherein CD30 expression is detected in at least 10% of malignant or atypical cells in a sample of the cancer. 3. The method of claim 2 wherein at least 50% of the malignant or atypical cells in the sample express CD30. 4. The method of claim 2 , wherein CD30 expression is detected in the cell membrane and/or Golgi of at least 10% of the malignant or atypical cells in the sample. 5. The method of claim 1 , wherein the patient has ovarian serous carcinoma. 6. The method of claim 1 , wherein the patient has triple negative breast cancer. 7. The method of claim 1 , wherein the patient has anaplastic thyroid carcinoma. 8. The method of claim 1 , wherein the patient has pancreatic carcinoma or adenocarcinoma. 9. The method of claim 1 , wherein the patient has small cell lung cancer. 10. The method of claim 1 , wherein the patient has anal squamous cell carcinoma. 11. The method of claim 1 , wherein the patient has Leydig cell tumor. 12. The method of claim 1 , wherein the patient has Sertoli cell tumor. 13. The method of claim 1 , wherein brentuximab vedotin is administered at a dose of 1.8 mg/kg every three weeks.
Assignees
Inventors
Classifications
- G01N33/5759Primary
involving compounds localised on the membrane of tumour or cancer cells · CPC title
against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title
NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95 · CPC title
the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11366118B2 cover?
- The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers.
- Who is the assignee on this patent?
- Seattle Genetics Inc, Seagen Inc
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5759. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).